V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214462 | 20080750 | 1.6 | 73 | Palliative (P) | 2016-12-09 | 2016-12-30 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100253857 |
| 20214464 | 20080752 | 1.83 | 73.4 | Palliative (P) | 2020-02-21 | 2020-02-24 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100150054 |
| 20214465 | 20080753 | 1.8 | 79.6 | null | 2018-07-29 | 2018-07-29 | LANREOTIDE | 02 | null | LANREOTIDE | 101717051 |
| 20214466 | 20080754 | 1.7 | 79 | Neo-adjuvant (N) | 2019-06-30 | 2019-07-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100100404 |
| 20214467 | 20080755 | 1.5 | 44 | Neo-adjuvant (N) | 2019-08-10 | 2019-09-06 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101569839 |
| 20214468 | 20080756 | 1.55 | 93.8 | Curative (C) | 2020-07-26 | 2020-08-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101508873 |
| 20214469 | 20080757 | 0 | 72.8 | 03 | 2018-12-19 | 2019-01-03 | IMATINIB | 02 | N | IMATINIB | 100658110 |
| 20214471 | 20080758 | 1.58 | 103.35 | Palliative (P) | 2018-12-29 | 2018-12-29 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 100243089 |
| 20214472 | 20080759 | 1.61 | 76.9 | Palliative (P) | 2016-07-12 | 2016-07-16 | LANREOTIDE | 02 | N | LANREOTIDE | 101407659 |
| 20214473 | 20080760 | 1.67 | 87 | Palliative (P) | 2018-05-22 | 2018-06-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101300224 |
| 20214474 | 20080761 | 1.77 | 79.3 | null | 2019-08-01 | 2019-08-05 | Cape+Cisplatin+Trastuzumab Load | 99 | null | LANREOTIDE | 101612884 |
| 20214475 | 20080762 | 1.63 | 72 | Palliative (P) | null | 2018-05-04 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101343985 |
| 20214478 | 20080764 | null | 0 | null | 2017-02-20 | 2017-03-21 | LANREOTIDE | 02 | null | LANREOTIDE | 101366315 |
| 20214479 | 20080765 | 0 | 93.25 | Neo-adjuvant (N) | 2016-08-29 | 2016-09-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101079619 |
| 20214480 | 20080766 | 1.76 | 69.45 | Curative (C) | 2016-10-07 | 2016-10-07 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100545463 |
| 20214481 | 20080767 | 1.59 | 84.3 | Palliative (P) | 2017-05-05 | 2017-05-05 | Trial Unspecified | 1 | N | TRIAL | 101155773 |
| 20214482 | 20080768 | 1.6 | 66 | Palliative (P) | 2017-06-30 | 2017-06-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101074940 |
| 20214484 | 20080769 | 1.73 | 68.3 | Palliative (P) | 2018-02-04 | 2018-02-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100126593 |
| 20214486 | 20080770 | 1.5 | 86.5 | Curative (C) | 2018-09-15 | 2018-09-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101826337 |
| 20214489 | 20080772 | 1.64 | 0 | null | 2020-01-29 | 2020-02-17 | HCX | 02 | null | LANREOTIDE | 100045376 |
| 20214490 | 20080773 | 1.57 | 102 | Palliative (P) | 2019-04-22 | 2019-04-25 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101507548 |
| 20214493 | 20080774 | 0 | 93.8 | 03 | 2018-09-15 | 2018-09-15 | LANREOTIDE | 02 | N | LANREOTIDE | 101786944 |
| 20214494 | 20080775 | 1.66 | 69.7 | Palliative (P) | 2016-10-20 | 2016-10-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100208802 |
| 20214495 | 20080776 | null | null | Palliative (P) | 2016-02-11 | 2016-02-11 | LANREOTIDE | 02 | N | LANREOTIDE | 100763499 |
| 20214496 | 20080777 | 1.9 | 54.9 | Palliative (P) | 2020-01-11 | 2020-01-12 | Trial Unspecified | Y | N | TRIAL | 101707501 |
| 20214498 | 20080778 | 1.8 | 46.8 | Palliative (P) | 2018-02-26 | 2018-02-26 | GO2 TRIAL | 01 | N | TRIAL | 101219978 |
| 20214501 | 20080780 | 1.6 | 0 | Curative (C) | 2018-05-13 | 2018-06-07 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100078022 |
| 20214502 | 20080781 | null | 65 | Curative (C) | 2017-11-12 | 2017-11-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100816440 |
| 20214503 | 20080782 | 1.7 | 0 | Palliative (P) | 2018-03-25 | 2018-03-28 | GO2 TRIAL | 1 | N | TRIAL | 101051475 |
| 20214504 | 20080783 | null | 70.2 | null | 2019-07-08 | 2019-07-21 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100910177 |
| 20214505 | 20080784 | 1.71 | 0 | Palliative (P) | 2019-10-26 | 2019-10-28 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100748869 |
| 20214506 | 20080785 | 0 | 68.7 | null | 2020-04-03 | 2020-04-19 | LANREOTIDE | 02 | N | LANREOTIDE | 100923963 |
| 20214507 | 20080786 | 1.82 | 68.8 | Palliative (P) | 2018-08-17 | 2018-08-24 | GO2 TRIAL | 01 | N | TRIAL | 100208832 |
| 20214508 | 20080787 | 1.75 | 118.6 | Palliative (P) | 2019-05-07 | 2019-05-11 | IMATINIB | 02 | N | IMATINIB | 101171974 |
| 20214509 | 20080788 | 1.7 | 50 | Palliative (P) | 2019-09-04 | 2019-09-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100103870 |
| 20214510 | 20080789 | 1.82 | 128 | Palliative (P) | 2020-10-21 | 2020-11-02 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100731853 |
| 20214513 | 20080790 | 1.65 | 92.4 | Palliative (P) | 2018-03-13 | 2018-04-15 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100416970 |
| 20214514 | 20080791 | 1.65 | 97 | Curative (C) | 2016-07-04 | 2016-07-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101089197 |
| 20214515 | 20080792 | null | null | Curative (C) | 2017-12-15 | 2017-12-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101633306 |
| 20214517 | 20080794 | 1.82 | 87.9 | 03 | 2017-09-28 | 2017-10-06 | Imatinib 400mg | 02 | N | IMATINIB | 101315403 |
| 20214519 | 20080795 | 1.72 | 66.2 | null | 2018-07-18 | 2018-07-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | TRIAL | 100791381 |
| 20214521 | 20080796 | 1.78 | 51.6 | null | 2017-05-29 | 2017-05-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101029473 |
| 20214522 | 20080797 | null | 68.3 | null | 2018-06-25 | 2018-06-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 101274449 |
| 20214524 | 20080798 | 1.68 | 72 | Curative (C) | 2018-01-14 | 2018-02-10 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101170279 |
| 20214527 | 20080799 | 1.72 | 73.8 | Palliative (P) | 2019-04-19 | 2019-04-29 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100960391 |
| 20214528 | 20080800 | 1.75 | 58.3 | Palliative (P) | 2018-09-24 | 2018-09-24 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101403495 |
| 20214529 | 20080801 | 1.86 | 80 | Palliative (P) | 2016-08-10 | 2016-08-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100024042 |
| 20214531 | 20080803 | 1.75 | 71.8 | null | null | 2017-10-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100381943 |
| 20214533 | 20080805 | 1.76 | 49.4 | Curative (C) | 2018-02-03 | 2018-02-16 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101072584 |
| 20214534 | 20080806 | null | null | 03 | 2019-02-06 | 2019-02-17 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100653583 |